Together, the congruent effects of Paqr8 overexpression and deletion in vivo and in vitro reinforce the conclusion that Paqr8 is both necessary and sufficient for tumor recurrence in the setting of Her2 inhibition, either by genetic downregulation or by pharmacological inhibition. This evidence concerns the gene ERBB2 and neoplasm.